Next Article in Journal
Regulation of Riboflavin Biosynthesis in Microorganisms and Construction of the Advanced Overproducers of This Vitamin
Previous Article in Journal
A Novel PLCζ Mutation Linked to Male Factor Infertility Induces a Gain-of-Function Effect on Ca2+ Oscillations in Eggs
Previous Article in Special Issue
Enhanced Analysis of Low-Abundance Proteins in Soybean Seeds Using Advanced Mass Spectrometry
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Mass Spectrometric Proteomics 3.0

1
Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, 27100 Pavia, Italy
2
Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2025, 26(13), 6242; https://doi.org/10.3390/ijms26136242
Submission received: 5 June 2025 / Accepted: 26 June 2025 / Published: 28 June 2025
(This article belongs to the Special Issue Mass Spectrometric Proteomics 3.0)
Mass spectrometry (MS) has undergone a profound transformation over the past two decades, expanding in both technical capability and scientific impact. Once primarily a tool for molecular weight determination, MS is now central to a wide range of disciplines, from proteomics and metabolomics to clinical diagnostics and environmental monitoring. This evolution has been driven by advances in high-resolution instrumentation, improved ionization techniques, and increasingly sophisticated data analysis platforms. As we enter what may be termed the “Mass Spectrometry 3.0” era, the field is being redefined by its integration with high-throughput workflows, artificial intelligence (AI), single-cell technologies, and real-time, in situ applications [1,2,3]. This Special Issue was conceived to capture and reflect on this pivotal phase. The articles collected here present the remarkable breadth and depth of modern MS-based research, particularly in proteomics, which has moved well beyond protein identification. Quantitative proteomics, single-cell analyses, post-translational modification (PTM) mapping, real-time metabolic flux tracking, and spatially resolved techniques expand the possibilities of what MS can achieve. More importantly, the integration of MS with other omics layers, such as transcriptomics, genomics, and metabolomics, facilitates integrating systems-level insights with complex biological processes [4]. At the same time, the field faces ongoing challenges. These include the need for enhanced sensitivity, greater specificity, robust data analysis pipelines, and standardized protocols, especially in clinical and regulatory settings [5]. The contributions in this Special Issue directly address these challenges. The featured studies present advances in sample preparation and enrichment, improved computational tools for data interpretation, and innovative strategies for accurate quantification in complex biological and clinical samples. Several articles also propose new metrics for evaluating proteome completeness and reproducibility, contributing to the development of best practices across the field. Looking ahead, the future of MS will be shaped by the convergence of analytical platforms, data science, and biology. Developments in miniaturization, real-time acquisition, and AI-driven data processing are expected to accelerate both the speed and accessibility of MS technologies. Furthermore, emerging directions such as ambient ionization, imaging MS, and lab-on-a-chip integration are paving the way toward real-time diagnostics and precision medicine at scale [6,7]. We hope this Special Issue serves not only as a snapshot of the current state of MS but also as a catalyst for new ideas and collaborations. The era of “Mass Spectrometry 3.0” is not defined by incremental progress alone; it is characterized by a reimagining of what is possible when this technology is embedded deep within molecular science.

Author Contributions

Conceptualization, P.I.; writing—original draft preparation, P.I. and S.V.; writing—review and editing, P.I. and S.V. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Aebersold, R.; Mann, M. Mass-spectrometric exploration of proteome structure and function. Nature 2016, 537, 347–355. [Google Scholar] [CrossRef] [PubMed]
  2. Alexandrov, T. Spatial Metabolomics and Imaging Mass Spectrometry in the Age of Artificial Intelligence. Annu. Rev. Biomed. Data Sci. 2020, 3, 61–87. [Google Scholar] [CrossRef] [PubMed]
  3. Messner, C.B.; Demichev, V.; Wang, Z.; Hartl, J.; Kustatscher, G.; Mülleder, M.; Ralser, M. Mass spectrometry-based high-throughput proteomics and its role in biomedical studies and systems biology. Proteomics 2023, 23, e2200013. [Google Scholar] [CrossRef] [PubMed]
  4. Taylor, M.J.; Lukowski, J.K.; Anderton, C.R. Spatially Resolved Mass Spectrometry at the Single Cell: Recent Innovations in Proteomics and Metabolomics. J. Am. Soc. Mass Spectrom. 2021, 32, 872–894. [Google Scholar] [CrossRef] [PubMed]
  5. Yu, S.; Zou, Y.; Ma, X.; Wang, D.; Luo, W.; Tang, Y.; Mu, D.; Zhang, R.; Cheng, X.; Qiu, L. Evolution of LC-MS/MS in clinical laboratories. Clin. Chim. Acta 2024, 555, 117797. [Google Scholar] [CrossRef]
  6. Zhang, H.; Zhang, J.; Yuan, C.; Zhang, D.; Lu, D.; Chen, S.; Wu, Y.; Wu, C. Recent advances in mass spectrometry imaging combined with artificial intelligence for spatially clarifying molecular profiles: Toward biomedical applications. TrAC Trends Anal. Chem. 2024, 178, 117834. [Google Scholar] [CrossRef]
  7. Zhai, Y.; Fu, X.; Xu, W. Miniature mass spectrometers and their potential for clinical point-of-care analysis. Mass Spectrom. Rev. 2024, 43, 1172–1191. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Iadarola, P.; Viglio, S. Mass Spectrometric Proteomics 3.0. Int. J. Mol. Sci. 2025, 26, 6242. https://doi.org/10.3390/ijms26136242

AMA Style

Iadarola P, Viglio S. Mass Spectrometric Proteomics 3.0. International Journal of Molecular Sciences. 2025; 26(13):6242. https://doi.org/10.3390/ijms26136242

Chicago/Turabian Style

Iadarola, Paolo, and Simona Viglio. 2025. "Mass Spectrometric Proteomics 3.0" International Journal of Molecular Sciences 26, no. 13: 6242. https://doi.org/10.3390/ijms26136242

APA Style

Iadarola, P., & Viglio, S. (2025). Mass Spectrometric Proteomics 3.0. International Journal of Molecular Sciences, 26(13), 6242. https://doi.org/10.3390/ijms26136242

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop